{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:23:11Z","timestamp":1788790991226,"version":"build-2803163510"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this study was to characterize age-specific adverse drug event profiles associated with vancomycin using real-world pharmacovigilance data, thereby advancing understanding of its safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The Food and Drug Administration Adverse Event Reporting System (FAERS) was used to collect data between the first quarter of 2019 and the third quarter of 2024. Disproportionality analysis was performed to detect vancomycin-related adverse event reports, with the study population stratified by age group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 8379 adverse event reports in which vancomycin was recorded as the primary suspect drug were retrieved: 981 (11.71%) in the 0\u201317 age group, 1763 (21.04%) in the 18\u201344 age group, 2705 (32.28%) in the 45\u201364 age group, and 2930 (34.97%) in the 65\u2009years and above group. The adverse events associated with vancomycin were involved 25 System Organ Class (SOC). \u201cInvestigations\u201d abnormalities (e.g., electrolyte disturbances) predominated in children; \u201cskin and subcutaneous tissue disorders\u201d in adults; and \u201cinfections and infestations\u201d in the elderly. Notably, high-risk preferred terms (PTs) showed non-overlapping across age strata. The strongest age-specific signals were \u201cblood electrolytes abnormal\u201d in 0\u201317\u00a0years, \u201cspinal stroke\u201d in 18\u201344\u00a0years, \u201cmyeloid maturation arrest\u201d in 45\u201364\u00a0years, and \u201chaemorrhagic occlusive retinal vasculitis\u201d in \u226565\u00a0years. In addition, our study identified several adverse events not explicitly described in current labeling; these totaled 32 events distributed across 13 SOCs, with the majority involving cardiac or nervous system disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Real-world data from the large-scale FAERS database were used to detect vancomycin-associated adverse event signals by disproportionality analysis, age-stratified comparisons revealed marked differences in adverse event signal. This pharmacovigilance research underscored potential safety concerns of vancomycin, corroborated known risks and identified novel safety signals not listed in the current product label. These findings expanded understanding of vancomycin\u2019s safety profile and provided evidence-based guidance for clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000004563","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:00:49Z","timestamp":1765983649000},"page":"9297-9309","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of age-specific adverse events with vancomycin: a real-world pharmacovigilance study based on the FAERS database"],"prefix":"10.1097","volume":"112","author":[{"given":"Zujun","family":"Wen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Heyuan People\u2019s Hospital, Heyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical and Pharmaceutical College, The Sixth People\u2019s Hospital of Chongqing, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical and Pharmaceutical College, The Sixth People\u2019s Hospital of Chongqing, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical and Pharmaceutical College, The Sixth People\u2019s Hospital of Chongqing, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Heyuan People\u2019s Hospital, Heyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Dazhou Central Hospital, Dazhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"R1-20260424","first-page":"694\u2013700","article-title":"The use of vancomycin with its therapeutic and adverse effects: a review","volume":"19","author":"Bruniera","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R2-20260424","doi-asserted-by":"crossref","first-page":"107109","DOI":"10.1016\/j.ijid.2024.107109","article-title":"Comparative effectiveness and safety of six antibiotics in treating MRSA infections: a network meta-analysis","volume":"146","author":"Ju","year":"2024","journal-title":"Int J Infect Dis"},{"key":"R3-20260424","first-page":"Cd004610","article-title":"Antibiotic treatment for clostridium difficile-associated diarrhoea in adults","volume":"3","author":"Nelson","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-20260424","doi-asserted-by":"crossref","first-page":"e0260539","DOI":"10.1371\/journal.pone.0260539","article-title":"Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: a systematic review and meta-analysis","volume":"16","author":"Jame","year":"2021","journal-title":"PLoS One"},{"key":"R6-20260424","first-page":"650\u201359","article-title":"Progresses on the prevalence and mechanism of vancomycin- resistant bacteria","volume":"47","author":"Shen","year":"2025","journal-title":"Yi Chuan"},{"key":"R7-20260424","doi-asserted-by":"crossref","first-page":"1516339","DOI":"10.3389\/fphar.2025.1516339","article-title":"Therapeutic vancomycin monitoring: a comparative analysis of high-performance liquid chromatography and chemiluminescent microparticle immunoassay methods in liver transplant recipients","volume":"16","author":"Azadi","year":"2025","journal-title":"Front Pharmacol"},{"key":"R8-20260424","doi-asserted-by":"crossref","first-page":"6\u201314","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R9-20260424","doi-asserted-by":"crossref","first-page":"335\u201367","DOI":"10.1007\/s40262-025-01494-4","article-title":"Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review","volume":"64","author":"Ngcobo","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"R10-20260424","doi-asserted-by":"crossref","first-page":"e00420","DOI":"10.1002\/prp2.420","article-title":"Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations","volume":"6","author":"Monteiro","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"R11-20260424","doi-asserted-by":"crossref","first-page":"1548376","DOI":"10.3389\/fphar.2025.1548376","article-title":"Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database","volume":"16","author":"Yang","year":"2025","journal-title":"Front Pharmacol"},{"key":"R12-20260424","doi-asserted-by":"crossref","DOI":"10.70389\/PJS.100082","article-title":"Transparency in the reporting of Artificial INtelligence \u2013 the TITAN guideline","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R13-20260424","doi-asserted-by":"crossref","first-page":"1366691","DOI":"10.3389\/fmed.2024.1366691","article-title":"Endocrine system-related adverse events associated with PD-1\/PD-L1 inhibitors: data mining from the FDA adverse event reporting system","volume":"11","author":"Shi","year":"2024","journal-title":"Front Med Lausanne"},{"key":"R14-20260424","doi-asserted-by":"crossref","first-page":"796\u2013803","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"R15-20260424","doi-asserted-by":"crossref","first-page":"1372401","DOI":"10.3389\/fphar.2024.1372401","article-title":"Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"R16-20260424","doi-asserted-by":"crossref","first-page":"20420986241311231","DOI":"10.1177\/20420986241311231","article-title":"Age-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA adverse event reporting system","volume":"16","author":"Mai","year":"2025","journal-title":"Ther Adv Drug Saf"},{"key":"R17-20260424","doi-asserted-by":"crossref","first-page":"3\u201310","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R18-20260424","doi-asserted-by":"crossref","first-page":"483\u201386","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R19-20260424","first-page":"1\u201311","article-title":"The safety profile of azithromycin in pediatrics: a pharmacovigilance disproportionality analysis","author":"Ren","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R20-20260424","doi-asserted-by":"crossref","first-page":"981\u201394","DOI":"10.1080\/14740338.2024.2368817","article-title":"The evolving role of disproportionality analysis in pharmacovigilance","volume":"23","author":"Fusaroli","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R21-20260424","doi-asserted-by":"crossref","first-page":"1708\u201314","DOI":"10.1093\/cid\/civ576","article-title":"Gender differences in rates of carriage and bloodstream infection caused by methicillin-resistant staphylococcus aureus: are they real, do they matter and why?","volume":"61","author":"Humphreys","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R22-20260424","doi-asserted-by":"crossref","first-page":"425\u201334","DOI":"10.1002\/phar.2941","article-title":"Vancomycin: an analysis and evaluation of eight population pharmacokinetic models for clinical application in general adult population","volume":"44","author":"Duong","year":"2024","journal-title":"Pharmacotherapy"},{"key":"R23-20260424","doi-asserted-by":"crossref","first-page":"1391356","DOI":"10.3389\/fphar.2024.1391356","article-title":"Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)","volume":"15","author":"Wen","year":"2024","journal-title":"Front Pharmacol"},{"key":"R24-20260424","doi-asserted-by":"crossref","first-page":"66\u201375","DOI":"10.7705\/biomedica.v27i1.234","article-title":"Reacciones adversas por antibi\u00f3ticos en una unidad de cuidado intensivo pedi\u00e1trico y neonatal de Bogot\u00e1","volume":"27","author":"Vallejos","year":"2007","journal-title":"Biom\u00e9dica"},{"key":"R25-20260424","doi-asserted-by":"crossref","first-page":"2056\u201363","DOI":"10.1002\/ptr.6391","article-title":"Rutin attenuates vancomycin-induced renal tubular cell apoptosis via suppression of apoptosis, mitochondrial dysfunction, and oxidative stress","volume":"33","author":"Qu","year":"2019","journal-title":"Phytother Res"},{"key":"R26-20260424","doi-asserted-by":"crossref","first-page":"1\u201313","DOI":"10.1093\/jac\/dkz325","article-title":"Mechanisms of antimicrobial-induced nephrotoxicity in children","volume":"75","author":"Downes","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R27-20260424","doi-asserted-by":"crossref","first-page":"2488139","DOI":"10.1080\/0886022X.2025.2488139","article-title":"The critical role of ion channels in kidney disease: perspective from AKI and CKD","volume":"47","author":"Csz","year":"2025","journal-title":"Ren Fail"},{"key":"R28-20260424","doi-asserted-by":"crossref","first-page":"666\u201374","DOI":"10.1093\/cid\/ciw811","article-title":"Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam","volume":"64","author":"Hammond","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R29-20260424","doi-asserted-by":"crossref","first-page":"85\u201397","DOI":"10.1159\/000513742","article-title":"Nephrotoxicity from vancomycin combined with piperacillin-tazobactam: a comprehensive review","volume":"52","author":"Blair","year":"2021","journal-title":"Am J Nephrol"},{"key":"R30-20260424","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.wneu.2021.12.082","article-title":"How safe is the use of intrathecal vancomycin?","volume":"160","author":"Demir","year":"2022","journal-title":"World Neurosurg"},{"key":"R31-20260424","first-page":"e12396","article-title":"Uncommon case of oral vancomycin neurotoxicity with sexual dysfunction","volume":"12","author":"Almohammadi","year":"2020","journal-title":"Cureus"},{"key":"R32-20260424","doi-asserted-by":"crossref","first-page":"425\u201327","DOI":"10.1007\/s00701-010-0810-7","article-title":"Cauda equina syndrome misdiagnosed as aggravated hydrocephalus: neurological complication of intrathecal colistin in post-surgical meningitis","volume":"153","author":"Kim","year":"2011","journal-title":"Acta Neurochir (Wien)"},{"key":"R33-20260424","doi-asserted-by":"crossref","first-page":"136415","DOI":"10.1016\/j.jhazmat.2024.136415","article-title":"Embryonic exposure to glycopeptides induces acute toxicity and developmental neurotoxicity in zebrafish (Danio rerio)","volume":"480","author":"Liu","year":"2024","journal-title":"J Hazard Mater"},{"key":"R34-20260424","doi-asserted-by":"crossref","first-page":"1283\u201393","DOI":"10.1080\/14740338.2024.2309225","article-title":"Hematological adverse events associated with anti-MRSA agents: a real-world analysis based on FAERS","volume":"23","author":"Yu","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R35-20260424","doi-asserted-by":"crossref","first-page":"868\u201372","DOI":"10.1016\/j.clinthera.2023.06.022","article-title":"Bleeding complications in vancomycin-Induced thrombocytopenia: a real-world postmarketing pharmacovigilance analysis","volume":"45","author":"Yang","year":"2023","journal-title":"Clin Ther"},{"key":"R36-20260424","doi-asserted-by":"crossref","first-page":"1058\u201364","DOI":"10.1086\/382356","article-title":"Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections","volume":"38","author":"Rao","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R37-20260424","first-page":"149\u201351","article-title":"Vancomycin-induced maturation arrest with reactive promyelocyte proliferation: a diagnostic and therapeutic challenge","volume":"15","author":"Jamal","year":"2023","journal-title":"J Lab Physicians"},{"key":"R38-20260424","doi-asserted-by":"crossref","first-page":"e931647","DOI":"10.12659\/AJCR.931647","article-title":"Thrombocytopenia, and eosinophilia: an unusual triad in a patient on long-term vancomycin therapy","volume":"22","author":"Lintel","year":"2021","journal-title":"Am J Case Rep"},{"key":"R39-20260424","doi-asserted-by":"crossref","first-page":"92\u201398","DOI":"10.1046\/j.1365-2249.2002.01720.x","article-title":"Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity","volume":"127","author":"Akamizu","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"R40-20260424","doi-asserted-by":"crossref","first-page":"904\u201310","DOI":"10.1056\/NEJMoa065066","article-title":"Vancomycin-induced immune thrombocytopenia","volume":"356","author":"Von Drygalski","year":"2007","journal-title":"N Engl J Med"},{"key":"R41-20260424","doi-asserted-by":"crossref","first-page":"338\u201342","DOI":"10.3928\/23258160-20140605-01","article-title":"Severe bilateral ischemic retinal vasculitis following cataract surgery","volume":"45","author":"Nicholson","year":"2014","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R42-20260424","doi-asserted-by":"crossref","first-page":"1438\u201351","DOI":"10.1016\/j.ophtha.2015.03.016","article-title":"Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin","volume":"122","author":"Witkin","year":"2015","journal-title":"Ophthalmology"},{"key":"R43-20260424","doi-asserted-by":"crossref","first-page":"583\u201395","DOI":"10.1016\/j.ophtha.2016.11.042","article-title":"Vancomycin-associated hemorrhagic occlusive retinal vasculitis: clinical characteristics of 36 eyes","volume":"124","author":"Witkin","year":"2017","journal-title":"Ophthalmology"},{"key":"R44-20260424","doi-asserted-by":"crossref","first-page":"52\u201355","DOI":"10.1097\/ICB.0000000000000725","article-title":"Hemorrhagic occlusive retinal vasculitis after intracameral vancomycin use in cataract surgery after intravenous exposure","volume":"15","author":"Alasil","year":"2021","journal-title":"Retin Cases Brief Rep"},{"key":"R45-20260424","doi-asserted-by":"crossref","first-page":"764\u201366","DOI":"10.3928\/23258160-20160808-10","article-title":"Hemorrhagic occlusive retinal vasculitis after first eye cataract surgery without subsequent second eye involvement","volume":"47","author":"Balducci","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R46-20260424","doi-asserted-by":"crossref","first-page":"702\u201312","DOI":"10.3928\/23258160-20221026-03","article-title":"Vancomycin-associated hemorrhagic occlusive retinal vasculitis: a case series and systematic review","volume":"53","author":"Matovi\u0107","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R47-20260424","doi-asserted-by":"crossref","first-page":"131\u201340","DOI":"10.1016\/j.ajo.2018.01.030","article-title":"Vancomycin-associated hemorrhagic occlusive retinal vasculitis: a clinical-pathophysiological analysis","volume":"188","author":"Todorich","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R48-20260424","doi-asserted-by":"crossref","first-page":"1012093","DOI":"10.3389\/fonc.2022.1012093","article-title":"Platinum drugs-related safety profile: the latest five-year analysis from FDA adverse event reporting system data","volume":"12","author":"Feng","year":"2022","journal-title":"Front Oncol"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:00:37Z","timestamp":1777057237000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000004563","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"2025-07-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}